Hudson Capital Management LLC Sells 2,310 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Hudson Capital Management LLC reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,792 shares of the biopharmaceutical company's stock after selling 2,310 shares during the quarter. Gilead Sciences accounts for approximately 1.8% of Hudson Capital Management LLC's investment portfolio, making the stock its 15th biggest holding. Hudson Capital Management LLC's holdings in Gilead Sciences were worth $6,027,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $1,789,254,000. FMR LLC raised its position in shares of Gilead Sciences by 21.6% in the fourth quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares during the period. GAMMA Investing LLC raised its position in shares of Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the period. Northern Trust Corp raised its position in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock valued at $1,377,707,000 after purchasing an additional 2,458,954 shares during the period. Finally, Raymond James Financial Inc. bought a new position in shares of Gilead Sciences in the fourth quarter valued at about $207,340,000. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Price Performance

Shares of GILD traded up $2.00 during mid-day trading on Friday, reaching $112.46. The company had a trading volume of 5,263,529 shares, compared to its average volume of 7,750,058. The company's 50 day simple moving average is $105.39 and its 200 day simple moving average is $101.47. Gilead Sciences, Inc. has a 1-year low of $62.69 and a 1-year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The company has a market capitalization of $139.89 billion, a price-to-earnings ratio of 303.95, a P/E/G ratio of 0.71 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. The business had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the company earned ($1.32) EPS. The firm's revenue was down .3% compared to the same quarter last year. Analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.81%. Gilead Sciences's dividend payout ratio is presently 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the transaction, the chief financial officer now owns 165,674 shares in the company, valued at approximately $16,537,578.68. This trade represents a 1.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the transaction, the chief executive officer now owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. The trade was a 1.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 60,929 shares of company stock worth $6,748,980 in the last ninety days. Company insiders own 0.27% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research report on Wednesday, February 12th. Oppenheimer lowered their price target on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research report on Friday, April 25th. Royal Bank of Canada raised their price target on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a research report on Wednesday, February 12th. BMO Capital Markets raised their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Finally, Bank of America raised their price target on shares of Gilead Sciences from $116.00 to $126.00 and gave the stock a "buy" rating in a research report on Wednesday, March 5th. Nine equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.